If Macri wins, Argentina's market should respond favorably. There are a few companies with exposure to Argentina to watch: 98% of Americas Petrogas's revenue comes from the country, 45% of Silver Standard's (SSRI - Get Report) total assets, 18% of Mercado Libre's (MELI - Get Report) revenue, and 8% of AMBEV's (ABEV - Get Report) revenue. These stocks might appreciate on news of Macri's potential victory.
if there is a miner to buy that will survive stronger then ever its SSRI and over time will be 25 to 30 dollars a share unless it gets bought out before then.
your short is way under and now you need to vent
Ocular Therapeutix ($OCUL) watched its share price fall nearly 40% on Friday after a pair of clinical trials came up short of success, clouding the future for two pipeline therapies.
The company's most advanced asset, a sustained-release formulation of the anti-inflammatory dexamethasone, came through with mixed results in a Phase III study on allergic conjunctivitis. The hydrogel drug, branded as Dextenza, met its first primary endpoint of relieving ocular itching related to conjunctivitis but missed the mark on its co-primary goal reducing redness,
Of the 613 participants who were sent surveys, 423 responded (69% response rate). Respondents self-identified as African American (n=127, 30%), Caucasian (n=284, 67%), and other ethnicity (n=12, 3%). In general, participants found the sDNA test more suitable than a colonoscopy (n=309, 75%). In univariate analyses, a higher percentage of Caucasians as compared with African Americans found the sDNA test more suitable than a colonoscopy (89% vs. 76%, p